F-1/A: IceCure Medical Seeks $37.8 Million Through Share and Warrant Offering

IceCure Medical Ltd. aims to raise capital by offering ordinary shares, pre-funded warrants, and accompanying warrants, with proceeds intended for business development, marketing, and R&D.

Summary

• IceCure Medical Ltd. is offering up to $37.8 million in securities, including ordinary shares, pre-funded warrants, and ordinary share purchase warrants.
• The offering includes up to 22,222,222 ordinary shares and accompanying warrants to purchase the same number of ordinary shares.
• Pre-funded warrants are also being offered as an alternative to ordinary shares for purchasers who would exceed beneficial ownership limitations.
• The assumed combined public offering price is $0.81 per ordinary share and accompanying warrant, with the warrant exercise price between $0.81 and $0.89.
• The warrants will expire either 30 days after the FDA marketing authorization of ProSense for early-stage low-risk breast cancer or five years from the issuance date.
• Maxim Group LLC is the lead placement agent, and Roth Capital Partners LLC is the co-placement agent for the offering.
• The net proceeds are intended for business development, marketing, research and development, and general corporate purposes.
• The offering is on a best efforts basis, with no minimum offering amount required.

Sentiment

Score: 6

Explanation: The document is neutral. It outlines the terms of a securities offering, which is a standard corporate finance activity. The inclusion of risk factors tempers any overly positive outlook.

Positives

• Funds raised will support business development and marketing activities.
• Funds raised will support research and development efforts.
• The company has engaged Maxim Group LLC and Roth Capital Partners LLC as placement agents.
• The offering includes pre-funded warrants, providing flexibility for investors with ownership limitations.

Negatives

• The offering is on a best efforts basis, meaning there's no guarantee of raising the full amount.
• The company's share price may be volatile.
• New investors will experience immediate dilution in the book value of their investment.
• There is no established public trading market for the warrants or pre-funded warrants.
• The company is subject to political, economic and military instability in Israel.

Risks

• The market price of the company's ordinary shares may be highly volatile.
• Future sales of ordinary shares could depress the market price.
• Management has broad discretion over the use of proceeds.
• Purchasers will incur immediate and substantial dilution in book value.
• There is no public market for the warrants or pre-funded warrants.
• The company's operations are subject to political, economic and military instability in Israel.
• The company may not be able to comply with Nasdaq continued listing requirements.

Future Outlook

The company expects a decision from the FDA regarding marketing authorization for ProSense in early-stage breast cancer in early 2025.

Industry Context

The company operates in the cryoablation systems and technologies market, offering minimally invasive alternatives to surgical interventions for tumors.

Stakeholder Impact

• Shareholders will be impacted by the potential dilution from the offering.
• Employees may benefit from the company's increased financial stability and growth opportunities.
• Customers may benefit from the company's ability to invest in research and development and improve its products.
• Suppliers may benefit from the company's increased financial stability and ability to pay its obligations.

Next Steps

• The company will file the Prospectus with the Commission pursuant to Rule 424(b).
• The company will seek to obtain the Required Approvals.
• The company will use commercially reasonable efforts to maintain the listing or quotation of the Ordinary Shares on the Trading Market.
• The company will apply to list or quote all of the Shares and Warrant Shares on such Trading Market and promptly secure the listing of all of the Shares and Warrant Shares on such Trading Market.

Key Dates

Keywords

warrants, offering, shares, icecure, medical, pre-funded, prosense, ordinary, medical, fda